Alkanol Group Only Between The Amino Nitrogen And An Ether Oxygen Which Is Bonded Directly To The Aryl Ring Or Aryl Ring System (i.e., Aryloxy Alkanol Amines) Patents (Class 514/652)
  • Patent number: 9040570
    Abstract: Provided are methods of treating or preventing a fungal infection in a subject. The methods comprise selecting a subject with or at risk of developing a fungal infection and administering to the subject a therapeutically effective amount of toremifene and fluconazole or derivatives thereof.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: May 26, 2015
    Assignee: University of Rochester
    Inventor: Damian J. Krysan
  • Publication number: 20150126473
    Abstract: The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle is useful in diagnostic assays, which are also provided.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 7, 2015
    Applicant: Children's Hospital & Research Center at Oakland
    Inventors: Ronald M. Krauss, Mohmed Elfatih Ashmaig
  • Patent number: 9005658
    Abstract: A pharmaceutical pellet is provided, comprising a spherical core containing the active substance with a smooth surface and a coating on the core, which controls pH-independent release of the active substance. With a pellet of this kind, the release of the active substance may follow a profile with a lag-phase from 60 minutes to 840 minutes, where during the lag-phase a proportion of 5 wt. % or less of the active substance is released. Furthermore, the active substance may be released from the pellet with a profile such that, after the lag-phase, the release of the active substance is between 3 and 25 wt. % per hour. The active substance is a metoprolol salt.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: April 14, 2015
    Assignee: ADD Advanced Drug Delivery Technologies Ltd.
    Inventors: Burkhard Schlutermann, Manfred Kohlmeyer
  • Patent number: 8999938
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: April 7, 2015
    Assignee: GNT LLC
    Inventor: Gerald Horn
  • Publication number: 20150087719
    Abstract: The present invention relates to aqueous non alcoholic solutions comprising a beta-blocker, a non sugar type sweetener and being substantially free of an aromatic preservative agent. The solutions of the present invention are particularly adapted for a paediatric use.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Inventors: Christine Chaumont, Jean-Francois Cordoliani, Elie Leverd, Valerie Muguet
  • Publication number: 20150064251
    Abstract: A tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
    Type: Application
    Filed: July 3, 2014
    Publication date: March 5, 2015
    Inventor: Isaac Ghebre-Sellassie
  • Patent number: 8962016
    Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.
    Type: Grant
    Filed: November 25, 2010
    Date of Patent: February 24, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
  • Patent number: 8927025
    Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: January 6, 2015
    Assignee: Cima Labs Inc.
    Inventor: Ehab Hamed
  • Publication number: 20140378401
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: December 18, 2013
    Publication date: December 25, 2014
    Applicant: GNT, LLC
    Inventor: Gerald Horn
  • Publication number: 20140378391
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 25, 2014
    Inventor: Gerald Horn
  • Publication number: 20140371322
    Abstract: A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about 20% by weight to about 99.95% by weight, with about 50% by weight being preferred. Permeation enhancer composition within disclosed phenoxybenzamine transdermal composition may improve penetration of phenoxybenzamine in a patient's tissue or skin. The phenoxybenzamine transdermal composition may provide a long duration blockade of sensitized pain receptors of 24 hours or more, resulting in an effective treatment for neuropathic pain with lower concentrations of phenoxybenzamine and requiring fewer applications.
    Type: Application
    Filed: June 13, 2013
    Publication date: December 18, 2014
    Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
    Inventor: Andrew B. Glasnapp
  • Patent number: 8906419
    Abstract: The present invention is directed to a process of preparing beads coated with a water soluble drug for incorporation into a pharmaceutical composition comprising: (a) preparing a supersaturated drug solution containing a desired amount of drug, which is completely saturated at a first temperature but which is supersaturated at a second temperature which is below the first temperature; and (b) coating inert beads with the drug solution, said drug solution being maintained at or below the first temperature but above the second temperature, and said beads maintained at a second temperature, wherein the second temperature is less than the first temperature and wherein the solution containing the drug is supersaturated at the second temperature, as well as to the pharmaceutical compositions containing same.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: December 9, 2014
    Assignee: Nostrum Pharmaceuticals, Inc.
    Inventor: Nirmal Mulye
  • Publication number: 20140357724
    Abstract: Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (?2) adrenoceptor antagonist, and in particular, the specific ?2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 4, 2014
    Applicant: Indiana University Research & Technology Corporation
    Inventor: Peng-Sheng Chen
  • Publication number: 20140322327
    Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.
    Type: Application
    Filed: November 15, 2012
    Publication date: October 30, 2014
    Applicant: UPM-KYMMENE CORPORATION
    Inventors: Antti Laukkanen, Ruzica Kolakovic, Leena Peltonen, Timo Laaksonen, Jouni Hirvonen, Heikki Lyytikainen, Harri Jukarainen, Prijo Kortesuo
  • Publication number: 20140294920
    Abstract: A transdermal d propranolol or racemic propranolol patch for use as an adjunct to surgery in the treatment of malignant melanoma and/or tattoo related applications are herein disclosed.
    Type: Application
    Filed: May 16, 2014
    Publication date: October 2, 2014
    Inventor: David J. Enscore
  • Publication number: 20140296242
    Abstract: Some embodiments of this invention include methods for treating disease and methods for administering a compound of the invention. In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of the invention. Pharmaceutical compositions of some embodiments of the present invention comprise a compound of the invention.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 2, 2014
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: J. Chistopher States, Ben Frazier Taylor, John O. Trent
  • Patent number: 8835505
    Abstract: A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol. The ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition is capable of being stored in a modified flexible plastic container that may be heat-sterilized without deformation and/or without having the integrity of the closure system being compromised. A method for the manufacture of the ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 16, 2014
    Assignees: Welgrace Research Group, HQ Specialty Pharma Corporation
    Inventors: George Owoo, Erica Castagna
  • Publication number: 20140255466
    Abstract: The present invention relates to a composition for enhancing transdermal absorption of a drug, containing a polyvalent alcohol having 3 to 8 carbon atoms, an organic acid having 2 to 20 carbon atoms, and a higher alcohol having 12 to 20 carbon atoms, and a patch preparation containing a support and a drug-containing adhesive layer containing the composition on one surface of the support.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Applicant: Nitto Denko Corporation
    Inventors: Tsuyoshi MUKOBATA, Arimichi OKAZAKI, Akinori HANATANI, Sachiko SAKAMOTO
  • Patent number: 8829054
    Abstract: A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol. The ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition is capable of being stored in a modified flexible plastic container that may be heat-sterilized without deformation and/or without having the integrity of the closure system being compromised. A method for the manufacture of the ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: September 9, 2014
    Assignees: Welgrace Research Group, HQ Specialty Pharma Corporation
    Inventors: George Owoo, Erica Castagna
  • Patent number: 8808731
    Abstract: An adhesive pharmaceutical preparation which has a less irritation to the skin surface, keeps excellent stability of bisoprolol in the preparation, and allows continuous administration of a pharmacologically effective amount of bisoprolol into the living body, is provided. The adhesive preparation 10 comprises a support 1, an adhesive layer 2 laminated on one surface of the support 1. The adhesive layer 2 is characterized by containing bisoprolol, polyisobutylene, tackifier, and an organic liquid ingredient compatible to polyisobutylene and tackifier. Thus, an adhesive pharmaceutical preparation which has a good adhesiveness with less irritation to the skin and which gives almost no pain at peel-off or removal from the skin surface with leaving almost no paste, can be provided. In addition, bisoprolol is very stably maintained in the preparation and a pharmacologically effective amount of bisoprolol can be administered continuously into the living body through the skin surface.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: August 19, 2014
    Assignees: Nitto Denko Corporation, Toa Eiyo Ltd.
    Inventors: Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa
  • Publication number: 20140187481
    Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 3, 2014
    Inventors: Arthur Tudor Tucker, Nigel Benjamin
  • Publication number: 20140178471
    Abstract: The present invention in general relates to a pharmaceutical dosage form comprising a multi-layered release formulation formed by co-extrusion. Said formulation in particular comprises a core layer comprising at least one polymer selected from polycaprolactone, ethylcellulose, or combinations thereof; and a coat layer comprising at least one (co)polymer selected from the list comprising: polyethylene oxide; polyethylene glycol; Basic Butylated Methacrylate (co)polymer; a (co)polymer of polyvinylcaprolactam, PEG and polyvinylacetate; or combinations thereof.
    Type: Application
    Filed: August 30, 2012
    Publication date: June 26, 2014
    Applicant: UNIVERSITEIT GENT
    Inventors: Jean Paul Remon, Chris Vervaet
  • Publication number: 20140170112
    Abstract: In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 19, 2014
    Applicant: VICUS THERAPEUTICS, LLC
    Inventors: John Maki, Newell Bascomb, Timothy J. Turner, Fredric Young
  • Publication number: 20140171490
    Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.
    Type: Application
    Filed: August 9, 2013
    Publication date: June 19, 2014
    Applicant: PHARMALINGT INC.
    Inventors: Yossi Gross, Rafi Herzog, Steven B. Koevary
  • Publication number: 20140141092
    Abstract: The invention discloses a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the gastric resistant coating layer comprises at least 30% by weight of a (meth)acrylate copolymer comprising polymerized units of 10 to 40% by weight of acrylic or methacrylic acid, 10 to 80% by weight of a C4- to C18-alkyl ester of acrylic or methacrylic acid and optionally 0 to 60% by weight of another vinylic monomer, whereby the release of the pharmaceutical or nutraceutical active ingredient is not more than 10% under in-vitro conditions at pH 1.2 after 2 hours in medium according to USP with and without the addition of 20% (v/v) ethanol.
    Type: Application
    Filed: June 12, 2012
    Publication date: May 22, 2014
    Applicant: Evonik Roehm GmbH
    Inventors: Jan Hendrik Schattka, Christian Meier, Herbert Jung, Hedi Krachtus, Jessica del Rosario Ferrand
  • Publication number: 20140142087
    Abstract: Compounds and combinations of them that inhibit phosphatidic phosphohydrolase (PAP) enzymatic activity are formulated into pharmaceuticals useful in cancer treatment. Inhibitors of PAP can be used for blocking the progression of cancers that depend on the epidermal growth factor receptor (EGFR), its oncogenic variants and other members of its ErbB tyrosine kinase receptor family, through induction of their endocytosis, thus making them inaccessible to the extracellular stimuli that promote maintenance and progression of cancer.
    Type: Application
    Filed: February 6, 2012
    Publication date: May 22, 2014
    Applicant: PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE
    Inventors: Alfonso Gonzalez, Andrea Soza, Claudia Metz
  • Publication number: 20140134246
    Abstract: Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 15, 2014
    Applicant: Aptalis Pharmatech, Inc.
    Inventors: Gopi VENKATESH, Vijaya SWAMINATHAN, Jin-Wang LAI
  • Patent number: 8716349
    Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: May 6, 2014
    Assignee: Algynomics Inc.
    Inventors: Luda Diatchenko, William Maixner
  • Patent number: 8716325
    Abstract: The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: May 6, 2014
    Assignee: PsiOxus Therapeutics Limited
    Inventor: David Cavalla
  • Patent number: 8716350
    Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 6, 2014
    Assignee: Algynomics Inc.
    Inventors: Luda Diatchenko, William Maixner
  • Patent number: 8710102
    Abstract: Compositions and methods for treating disorders of the outer retina with ?-adrenoceptor antagonists are disclosed.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Robert J. Collier, Jr., Michael A. Kapin, Louis DeSantis, Jr.
  • Patent number: 8703178
    Abstract: The present invention relates to a percutaneous administration device of bisoprolol, which includes a backing; and a pressure-sensitive adhesive layer containing bisoprolol, which is laminated on one surface of the backing, wherein the maximum value of a release rate of bisoprolol during a period of from immediately after the application on skin until a lapse of 24 hours is 30 ?g/cm2/hr or less; and wherein the release rate of bisoprolol at the time of a lapse of 24 hours after the application on skin is 10 ?g/cm2/hr or less. The percutaneous administration device of the present invention is reduced in the skin irritation during the application, especially at the time of peeling, and is capable of persistently administrating a therapeutically or preventively effective amount of bisoprolol into a living body.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: April 22, 2014
    Assignees: Nitto Denko Corporation, Toa Eiyo Ltd.
    Inventors: Yoshihiro Iwao, Kensuke Matsuoka, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa
  • Patent number: 8680157
    Abstract: The invention relates to the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to assay systems allowing to test LSD1 inhibitors for their ability to inhibit LSD1 function.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: March 25, 2014
    Assignee: Universitaetsklinikum Freiburg
    Inventors: Roland Schuele, Eric Metzger
  • Publication number: 20140065217
    Abstract: A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement, Pompilia Ispas-Szabo
  • Publication number: 20140044787
    Abstract: The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises: (a) a therapeutically effective amount of a medicament; (b) 0.5 to 50% by weight of a water-soluble polymer; and (c) 1 to 25% by weight of a water-insoluble polymer applied as an aqueous latex dispersion and subsequently the water is removed, wherein the sum of the percentages of the medicament, the water-insoluble polymer and the water-soluble polymer is equal to or less than 100%. It also discloses methods of making this composition.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 13, 2014
    Applicant: NOSTRUM PHARMACEUTICALS, LLC
    Inventor: Nirmal MULYE
  • Publication number: 20130345150
    Abstract: An ophthalmic composition comprising a polyaphron dispersion.
    Type: Application
    Filed: March 14, 2012
    Publication date: December 26, 2013
    Inventor: Fraser Steele
  • Publication number: 20130338194
    Abstract: Disclosed herein are methods of and systems for predicting recurrence of atrial fibrillation comprising protease and protease inhibitor profiling.
    Type: Application
    Filed: November 11, 2011
    Publication date: December 19, 2013
    Applicant: MEDICAL UNIVERSITY OF SOUTH CAROLINA
    Inventors: Rupak Mukherjee, Michael R. Gold, Francis G. Spinale
  • Publication number: 20130338143
    Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
    Type: Application
    Filed: November 15, 2011
    Publication date: December 19, 2013
    Applicant: Neuroderm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawozink
  • Publication number: 20130317030
    Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
    Type: Application
    Filed: March 7, 2013
    Publication date: November 28, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
  • Publication number: 20130303473
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicant: NOVALIQ GmbH
    Inventor: Clive G. Wilson
  • Publication number: 20130296416
    Abstract: Provided are methods of treating heart failure in children using B1-selective adrenergic receptor antagonists, alone or in combination with other agents, including B-2-selective adrenergic receptor agonists.
    Type: Application
    Filed: August 25, 2011
    Publication date: November 7, 2013
    Applicant: The Regents of the University of Colorado, A Body Corporate
    Inventors: Brian Stauffer, Carmen Sucharov, Shelley Miyamoto
  • Publication number: 20130266660
    Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
    Type: Application
    Filed: May 9, 2011
    Publication date: October 10, 2013
    Applicant: CIMA LABS Inc.
    Inventor: Ehab Hamed
  • Publication number: 20130261178
    Abstract: A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstituted and substituted C3-C3 cycloalkyl, C1-C8 linear or branched alkyl, C2-5 alkenyl, C6-C10 heteroaryl or aryl, or C3-C8 heterocyclyl which may be part unsaturated, and combinations thereof; Z is linear C2-3 alkylene; X1 is selected from NH and O; X2 is selected from unsaturated C and unsaturated S; and X3 is selected from NH and CH2; or one of X1 and X3 is a single bond; or X1 is O and X2 and X3 together are a single bond; and R7 is selected from oxo, F, Cl, Br, CN, NH2, NR92, NO2, CF3, OR9, COR9, OCOR9, COOR9, NR9COR9, CONR92SO2NR92, NR9SO2R9; and R8 is selected from C1-5 alkyl, C1-5 alkoxyl, C2-5 alkenyl or alkynyl, C6-10 aryl and C3-8 cycloalkyl and combinations thereof, which may be unsubstituted or further substituted by one or more F, Cl, Br, CN, NH2, NR32, NO2, CF3;
    Type: Application
    Filed: July 5, 2010
    Publication date: October 3, 2013
    Inventors: Shailesh Mistry, Etienne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
  • Patent number: 8524273
    Abstract: A transdermal absorption preparation having a support and a pressure-sensitive adhesive layer consisting of multiple layers, wherein the pressure-sensitive adhesive layer comprises a drug-retaining layer containing a drug and an acrylic pressure-sensitive adhesive and a skin adhesion layer containing a styrene-isoprene-styrene block copolymer. This preparation can continuously release bisoprolol at a constant concentration. Moreover, it can be easily produced.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: September 3, 2013
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Satoshi Amano, Sachiko Honma, Tetsuro Tateishi, Natsumi Kase
  • Publication number: 20130225688
    Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 29, 2013
    Applicant: ALGYNOMICS INC.
    Inventor: Algynomics Inc.
  • Patent number: 8519005
    Abstract: Effects of deprenyl or propargylamine compounds (MAO inhibitors) and novel compositions comprising at least one MAO inhibitor and at least one antiinflammatory agent such as nonsteroidal antiinflammatory drugs (NSAIDS), steroids, acetaminophen (COX-3 inhibitors), 5-lipoxygenase inhibitors, leukotriene receptor antagonists, leukotriene A4 hydrolase inhibitors, antihistaminics, histamine 2 receptor antagonists, phosphodiesterase-4 antagonists, cytokine antagonists, CD44 antagonists, antineoplastic agents, 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins), estrogens, androgens, antiplatelet agents, antidepressants, Helicobacter pylori inhibitors, proton pump inhibitors, thiazolidinediones, dual-action compounds, combinations of these drugs with other agents, derivatives and metabolites of synthetic and natural antiinflammatory agents.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: August 27, 2013
    Inventor: Thomas N. Thomas
  • Publication number: 20130202705
    Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance.
    Type: Application
    Filed: May 9, 2011
    Publication date: August 8, 2013
    Applicant: Cima Labs Inc.
    Inventor: Ehab Hamed
  • Publication number: 20130171199
    Abstract: An oral controlled release pharmaceutical composition comprising a core and a polymer dispersion and its preparation method are disclosed. The core is selected from the group consisting of ‘the drug coated core’ and ‘the drug loaded core’. The drug coated core comprises an inert excipient based sphere and a coat of drug composition. The drug loaded core comprises at least a drug, a binder and at least one pharmaceutically acceptable excipient. The polymer dispersion used to coat the core comprises at least one controlled release polymer and at least one pharmaceutically acceptable excipient. The oral controlled release pharmaceutical composition further comprises an in-situ gelling system comprising at least one gelling polymer.
    Type: Application
    Filed: December 20, 2010
    Publication date: July 4, 2013
    Applicant: Abbott Healthcare Private Limited
    Inventors: Sanjay Boldhane, Shripad Jathar, Maneesh Nerurkar
  • Publication number: 20130143869
    Abstract: Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity.
    Type: Application
    Filed: July 14, 2011
    Publication date: June 6, 2013
    Applicant: Merz Pharma GmbH & CO. KGaA
    Inventors: Kevin Kiehm, Bernhard Hauptmeier, Harry Abts, Peter Boderke
  • Publication number: 20130131181
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Application
    Filed: November 16, 2012
    Publication date: May 23, 2013
    Applicant: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2
    Inventor: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2